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IMPORTANCE Whether and under which conditions D-cycloserine (DCS) augments the effects
of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and
posttraumatic stress disorders is unclear.
OBJECTIVE To clarify whether DCS is superior to placebo in augmenting the effects of
cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress
disorders and to evaluate whether antidepressants interact with DCS and the effect of
potential moderating variables.
DATA SOURCES PubMed, EMBASE, and PsycINFOwere searched from inception to February
10, 2016. Reference lists of previous reviews andmeta-analyses and reports of randomized
clinical trials were also checked.
STUDY SELECTION Studies were eligible for inclusion if they were (1) double-blind randomized
clinical trials of DCS as an augmentation strategy for exposure-based cognitive behavior
therapy and (2) conducted in humans diagnosed as having specific phobia, social anxiety
disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, or
posttraumatic stress disorder.
DATA EXTRACTION AND SYNTHESIS Raw data were obtained from the authors and quality
controlled. Data were ranked to ensure a consistent metric across studies (score range,
0-100). We used a 3-level multilevel model nesting repeatedmeasures of outcomes within
participants, who were nested within studies.
RESULTS Individual participant data were obtained for 21 of 22 eligible trials, representing
1047 of 1073 eligible participants. When controlling for antidepressant use, participants
receiving DCS showed greater improvement from pretreatment to posttreatment (mean
difference, −3.62; 95% CI, −0.81 to −6.43; P = .01; d = −0.25) but not from pretreatment to
midtreatment (mean difference, −1.66; 95% CI, −4.92 to 1.60; P = .32; d = −0.14) or from
pretreatment to follow-up (mean difference, −2.98, 95% CI, −5.99 to 0.03; P = .05;
d = −0.19). Additional analyses showed that participants assigned to DCS were associated
with lower symptom severity than those assigned to placebo at posttreatment and at
follow-up. Antidepressants did not moderate the effects of DCS. None of the prespecified
patient-level or study-level moderators was associated with outcomes.
CONCLUSIONS AND RELEVANCE D-cycloserine is associated with a small augmentation effect
on exposure-based therapy. This effect is not moderated by the concurrent use of
antidepressants. Further research is needed to identify patient and/or therapy characteristics
associated with DCS response.
JAMA Psychiatry. 2017;74(5):501-510. doi:10.1001/jamapsychiatry.2016.3955
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A nxiety, obsessive-compulsive, and posttraumaticstress disorders constitute the most prevalent groupof mental disorders, collectively affecting up to 30%
of individuals at some point in their lives.1 These conditions
contribute significantly to the global burden of disease and
disability-adjusted life-years.2
First-line treatments for theseconditions includecognitive
behavior therapy (CBT), typically involvingexposure to feared
stimuli,3-9 andmedication,primarily selective serotonin reup-
take inhibitors.3-10While there is ample support for theefficacy
of CBT and selective serotonin reuptake inhibitors, a substan-
tial proportion of patients do not achieve sufficient symptom
reliefandrequireadditional long-termcare. Ingeneral, thecom-
bination of these treatment modalities is not superior to CBT
alone inthe longrun11-13 andmayinfacthavedeleteriouseffects
and result in increased relapse rates after discontinuation of
medication.14,15 In lightof these results, researchershavebegun
exploring other ways to augment the effects of CBT.16,17
One promising strategy is the administration of D-
cycloserine (DCS), a partialN-methyl-D-aspartate agonist that
facilitates fear extinction in animals and reduces returnof fear
when given before or shortly after extinction training.16 De-
spite several initial trials showing promising results in hu-
manswithanxietydisorders,18-20 larger trials conductedwithin
the past 5 years21,22 have produced mixed results.23-26 Re-
search suggests that DCS may only enhance CBT under cer-
tain conditions.21,22,27 Variables, such as the number of CBT
sessions, thedoseandnumberofDCSadministrations, the tim-
ing of drug administration, the success of the exposure ses-
sions, or compliancewithbetween-sessionhomeworkassign-
ments,may also contribute to the conflicting results obtained
to date.26 Further, a large trial in obsessive-compulsive
disorder22 found a significant interaction effect betweenDCS
and antidepressant medication in a post hoc analysis; con-
comitant antidepressants impaired treatment response in pa-
tients randomized to DCS but not in patients randomized to
placebo. These results, which are consistent with the animal
literature,28-30 suggest that DCSmay only be indicated in pa-
tients who are not receiving antidepressants, but these re-
sults require replication.
Theprimaryaimsof this 1-stage individualparticipantdata
(IPD)meta-analysis were to help clarifywhether DCS is supe-
rior toplacebo inaugmenting theeffectsofCBTforanxietydis-
orders after adjusting for antidepressant use and to evaluate
whether antidepressants interactwithDCS to reduce its facili-
tatingeffectsonCBT.Secondaryaimswere toexaminehowthe
following variables affect ormoderate the effects of DCS: age,
sex, age group (child vs adult), primary diagnosis, number of
exposure sessions, DCS dose, timing of administration, and
number of DCS administrations. Additionally, we examined
whetherDCS led to faster improvementof symptomsbyexam-
ining theeffect ofDCSvsplaceboatmidtreatment. Individual-
participantdatameta-analysesareconsideredthegoldstandard
ofmeta-analysis and offer a number of important advantages
over traditionalmeta-analyses that relyonsummarystatistics,
includingthebettercontrolofpatient-levelandstudy-levelcon-
founders and increasedpower fordetecting interactioneffects
and subgroup analyses.31,32
Methods
Protocol and Registration
Thereviewwasconductedusing thePreferredReporting Items
for Systematic Reviews andMeta-Analyses of Individual Par-
ticipantData (checklist andprotocol).31 Thestudyprotocolwas
registeredwithPROSPERO (CRD42015025359) and it is acces-
sible from http://www.crd.york.ac.uk/PROSPERO/display
_record.asp?ID=CRD42015025359.
Eligibility Criteria
Studieswere eligible for inclusion if theywere (1) published or
unpublished double-blind, randomized, placebo-controlled
trials of DCS as an augmentation strategy for CBT or behavior
therapy incorporating exposure or exposure with response
prevention techniques or experimental studies including
asingle-exposure sessionand (2) conductedwithhumanswith
a diagnosis of specific phobia, social anxiety disorder, panic
disorder with or without agoraphobia, obsessive-compulsive
disorder, or posttraumatic stress disorder. For the specific
phobia studies, the impairment/interference criterion re-
quired for the diagnosis was waived to allow the inclusion of
fearful individualswhowere not significantly impaired given
the sporadic appearance of the phobic stimulus in their
daily lives.
Information Sources and Search
Twoauthors (B.M.andA.P.-V.) conductedan independent sys-
tematic, 2-step literature search to identify relevant articles.
First, PubMed,EMBASE,andPsycINFOwere searched fromin-
ception to February 10, 2016. Second,manual searches of the
reference lists of eligible articles and previous reviews and
meta-analyses of aggregate data were performed. Addition-
ally, key authors in the field were contacted for unpublished
data.
The searchwasperformedusing searchalgorithms includ-
ing the terms D-cycloserine [and related terms]; CBT, behav-
ior therapy, or exposure therapy [and related terms]; and any
of the diagnoses of interest (eMethods 1 in the Supplement).
No restrictions were set. Results from the 3 blocks were com-
bined and duplicates removed.
Key Points
Question Does D-cycloserine (DCS) augment the effects of
exposure-based therapy for anxiety, obsessive-compulsive, and
posttraumatic stress disorders?
Findings In thismeta-analysis of individual participant data from
21 trials, when controlling for antidepressant use, participants
receiving DCS showed greater improvement frompretreatment
to posttreatment but not frompretreatment tomidtreatment or
frompretreatment to follow-up. Effect sizeswere small, and
antidepressants did notmoderate the effects of DCS.
Meaning Further research is needed to identify patient and/or
therapy characteristics associatedwith theDCSaugmentation
effect.
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Study Selection and Data Collection Processes
Eligibility of trials was assessed independently by 2 authors
(B.M. and A.P.-V.). Any differences in opinion regarding eligi-
bility were resolved by discussion.
Corresponding authors of all eligible studies were con-
tacted and informed via email. Those who were able to con-
tributewereaskedtoprovideanonymizeddata fromtheir stud-
ies using a prespecified template. Data from the individual
studies provided were quality controlled and subsequently
merged for analysis. For those studieswhere IPDwasnotavail-
able, data items were extracted from the publications.
Data Items
The requested IPD included the anonymousparticipant num-
ber, sex, age, condition (DCSvsplacebo),numberofDCSorpla-
cebo administrations, time of pill administration (ie, number
ofminutesbefore/after theexposuresessions),DCSdose(inmil-
ligrams), concomitant antidepressant medication (present/
absent,drugname,anddose),numberofCBTsessions,andout-
comesatmajor treatment timepoints (baseline,midtreatment,
posttreatment, andfollow-up)asmeasuredbytheprimaryout-
come measure stipulated by the authors in each individual
study. Because different primary outcomemeasures had dif-
ferent score ranges anddata distributions across studies, out-
comemeasureswereharmonized.Specifically,wetransformed
the original data into ranked data to ensure a commonmetric
across studies (score range, 0-100). This is described in detail
in the eMethods 2 in the Supplement.
Individual Participant Data Integrity
Two authors (B.M. and L.F.C.) independently assessed IPD
data sets,withqueries resolvedbya thirdauthor (D.M.-C.).The
data were checked with respect to range, missing or extreme
values, errors, and consistencywith the published data. Trial
details, such as randomizationmethods and intervention de-
tails, were crosschecked against the original publications. In-
consistenciesormissingdatawerediscussedandresolvedwith
the collaborators. Each trialwas checked individually, and the
trial data were sent to the original authors for verification.
Risk of Bias Assessment in Individual Studies
and Across Studies
Eligibility criteriawereprospectivelydefined, andall relevant
publishedandunpublished trialsweresought toavoidbias.We
checked forunusual allocationpatternsordistributionsofpar-
ticipant characteristics and checkedwhether therewere trials
with inappropriateallocation.Weestablishedwhetheranyran-
domizedparticipantdatawerenot included in thedatasets (eg,
if authors conductedanalysesbasedoncompletersonly,were-
quested all data on randomized patients in order to perform
intent-to-treatanalyses).Weexcludedanynonrandomizedpar-
ticipants from thedata sets. TheCochraneCollaborationTool
forAssessingRiskofBias33,34wasused(posthoc) toexplorepos-
sible bias in the individual studies.
Synthesis Methods
We conducted a 1-stage IPDmeta-analysis. We used a 3-level
multilevel model (MLM) nesting repeated measures of out-
comewithinparticipants,whowerenestedwithinstudies.Our
MLManalyses, performedusingHierarchical Linear andNon-
linear Modeling version 7.01 (Scientific Software Interna-
tional Inc),were coded toperform theMLMequivalent of a re-
peated-measures analysis of covariance, allowing slopes and
intercepts to vary between studies and retaining all partici-
pants even if theymissed assessments or dropped out (ie, in-
tent-to-treat analyses). α Values were 2-tailed, and statistical
significance was set at .05.
Our primary analyses examined (1) whether DCS led to
greater improvement than placebo after adjusting for antide-
pressant use and (2) whether antidepressant use moderated
the effect of treatment condition (DCS vs placebo) on out-
come. Planned secondary analyses examined other possible
moderators of the treatment conditioneffect (listed in thepre-
vious section). Post hoc, it was determined that sample size,
year of publication, and study quality (risk of bias)were addi-
tional variables that were available and may moderate treat-
ment condition effects. Thus, they were added to the mod-
erator analysis.
To model a repeated-measures analysis of covariance in
MLM, the growth curve consisted of 3 dummy variables that
modeled the change frompretreatment tomidtreatment, pre-
treatmenttoposttreatment,andpretreatmenttofollow-up.Each
moderator, including antidepressant use, was tested by add-
ing themoderatorandthemoderator × treatmentcondition in-
teractionaspredictorsof the interceptandeachof the3“slopes”
(pretreatment to midtreatment, pretreatment to posttreat-
ment,andpretreatmenttofollow-up).Moderatorvariableswere
converted to z scores to facilitate comparison between mod-
erators and to center themat theirmean.Treatmentgroupwas
also centeredat itsmean.Thecoding for thedichotomousvari-
ables was as follows: group: placebo = 0 and DCS = 1; sex:
men = 0 and women = 1; child vs adult studies: child = 0 and
adult = 1; anddiagnosis: each diagnosiswas coded as 1 for that
diagnosis and as 0 for other diagnoses. To calculate the timing
ofadministrationvariable, thestart timeof thesessionwassub-
tracted fromthe timeof the administrationof thepill,with the
result coded in minutes (negative numbers on this scale indi-
cate that DCSwas administered before the start of the session,
whilepositivenumbers indicate thatDCSwasadministeredaf-
ter the start of the session). Standardizedeffect sizes (theMLM
equivalent of Cohen d) were calculated for all significant ef-
fects using the techniques developed by Raudenbush and
Xiao-Feng35orFeingold,36asappropriate.Becausecliniciansand
researchersmaybe specifically interested in the effects ofDCS
for each type of diagnosis, subgroup analyseswere conducted
for each primary diagnosis using identical models.
Power analyses, performed using Optimal Design, indi-
cated greater than 0.80 power to detect small effect sizes
(Cohen d = 0.20) for individual-level effects, including the
treatmentgroupeffectand individual-levelmoderators (eg, sex
and age). On the other hand, because therewere only 21 stud-
ies, the power to detect even a large effect size (d = 0.80) for
the study-levelmoderators/predictors (eg, sample size anddi-
agnosis) was only approximately 0.70 for single predictors
(eg, sample size) andonly about0.40 fordiagnosis,whichwas
comprised of 4 dummy variables.
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Results
Study Selection and IPDObtained
Of the 377 studies that were initially identified and analyzed
for eligibility, 22 studiesmet inclusion criteria (Figure 1). The
22eligible trials included 1073participants, including 124with
specific phobia, 291with social anxietydisorder, 77withpanic
disorder with or without agoraphobia, 292 with obsessive-
compulsive disorder, and 289 with posttraumatic stress
disorder.18-22,37-53 Study characteristics of the 22 eligible stud-
ies are presented in eTable 1 in the Supplement.
Wewereable toobtain IPDfrom21of these22studies.Data
from26participants included inoneposttraumatic stress dis-
order study50 could not be included because the local ethics
committeedidnot allowdata sharing.Therefore, the finaldata
set included 1047 patients (523 receiving DCS and 521 receiv-
ingplacebo; for 3additionalpatients, thegroupallocationvari-
ablewasmissing),which, to our knowledge, represents 97.6%
of the available data. Four of 21 studies were pediatric. The
mean (SD) age of the whole sample was 32.1 (13.5) years. The
samplewasevenlysplitbysex,with516women(49.4%).About
one-quarter of the sample (275 [26.9%]) were receiving anti-
depressants (eTable2 in theSupplement).Themean (SD)num-
ber of treatment sessions was 7.6 (4.5).
IPD Integrity and Risk of BiasWithin Studies
Discrepancies between the provided IPD and the original re-
ports were found in 16 of 21 studies. Twenty-nine mis-
matches were found, most of which were related to different
numbers of patients receiving antidepressant medication re-
ported in thepublicationvs thedata set. All discrepancies, ex-
cept foramismatchonthemedicationbreakdown inonestudy
(wherewe assumed that the actual data setwas correct) were
successfully resolved by correspondence with the authors.
Authors of 5 of the included studieswere contacted to re-
questmissing data. Allmissing datawere provided except for
the age variable in one of the studies.
Correspondingauthorsof6of theeligible studieswerecon-
tacted to request data on all randomized participants be-
cause initially only information on completers had been pro-
vided. Data were received for 31 noncompleters who had
originally been omitted from the data sets. Additionally, one
of the data sets included 2 nonrandomized participants who
were excluded prior to analysis.
Results of Individual Studies
Datawere obtained for all participantswhowere initially ran-
domized in each of the studies for which IPD were available.
Between-group (DCSvsplacebo)Cohend effect sizes and95%
CIs at posttreatment for each individual study based on raw
data are shown in eTable 3 in the Supplement.
Results of Syntheses (Primary Aim)
We identified 11 different primary outcomes measures in the
included studies (eTable 1 in the Supplement). As expected,
the different outcomemeasures haddifferent ranges anddis-
tributions (eFigure in theSupplement), and therefore, thedata
were transformed to ensure a common measurement across
studies (eMethods 2 in the Supplement).
Initial exploratory analyses to determine the overall ef-
fect of DCS vs placebo showed that improvementwas greater
in those who received DCS than those who received placebo
frompretreatment toposttreatment (difference,−3.93;95%CI,
−1.16 to −6.70; P = .006, d = −0.27) and frompretreatment to
follow-up (difference, −3.32; 95% CI, −0.34 to −6.30; P = .03,
d = −0.21) but not frompretreatment tomidtreatment (differ-
ence, −1.69; 95% CI, −1.51 to −4.89; P = .30) (eTable 4 in the
Supplement). Theseanalyses also showed thatparticipants re-
ceivingDCShad lower symptomseverity thanparticipants re-
ceiving placebo at posttreatment (difference, −3.34; 95% CI,
−1.12 to −5.56; P = .004, d = −0.22) and at follow-up (differ-
ence, −2.73, 95%CI, −0.25 to −5.21;P = .03;d = −0.18) (eTable
4 in the Supplement).
To investigateprimaryaim1,weranthis sameanalysis con-
trolling for antidepressant use as a moderator of the DCS ef-
Figure 1. PRISMA Individual Participant Data (IPD) Flowchart
for the Study
0 Additional studies identified
through other sources including
contact with researcher
376 Studies after duplicates removed 
376 Studies screened for eligibility
22 Studies for which IPD were sought 
0 Eligible studies for which IPD were
not sought  
97 PubMed
333 Embase
124 PsycINFO
Studies identified through database
searching:
354 Studies excluded:
282 Not randomized clinical trial
34 Not on disorders of interest
14 Not on humans
12 Not testing D-cycloserine in
addition to cognitive
behavior therapy
9 Secondary analysis 
2 Without a clinical diagnosis
1 Not double-blinded
21 Studies for which IPD were
provided
1047 Participants for whom
data were provided
0 Participants for whom
no data were provided
IPD (report for each main outcome)
21 Studies included in analysis
1047 Participants included in analysis
0 Participants excluded
Aggregate data (report for each main
outcome)
22 Studies included in analysis
1073 Participants included in analysis
0 Participants excluded
1 Study for which IPD were not
provided (ethical approval to share
data not granted)
26 Participants
22 Studies for which aggregate data
were available
1073 Participants
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fects (Table 1). Participants receiving DCS showed greater im-
provement than those receivingplacebo frompretreatment to
posttreatment (difference, −3.62; 95% CI, −0.81 to −6.43,
P = .01, d = −0.25), but not from pretreatment to midtreat-
ment (difference, −1.66, 95% CI, −4.92 to 1.60; P = .32;
d = −0.14)or frompretreatment to follow-up(difference,−2.98;
95% CI, −5.99 to 0.03; P = .05; d = −0.19) (Table 1; Figure 2).
Additionalposthocanalyses also revealed thatparticipants re-
ceivingDCSevidenced lower symptomseverity than those re-
ceiving placebo at bothposttreatment (difference, −3.19; 95%
CI, −0.95 to −5.43; P = .006; d = −0.21) and at follow-up (dif-
ference, −2.54; 95% CI, −0.04 to −5.04; P = .05; d = −0.16).
The same model was used to address primary aim 2. Re-
sults showed that antidepressant use didnotmoderate anyof
the effects of DCS on outcome (Table 1). However,we did find
that regardless of randomized treatment condition, partici-
pants taking antidepressants improved more from pretreat-
ment to follow-up than those not taking antidepressants (dif-
ference, −4.32; 95% CI, −0.64 to −8.01; P = .02, d = −0.28)
(Table 1).
Moderator Analyses (Secondary Aim)
The randomeffects for the improvement frompretreatment to
midtreatment(χ210 = 144.02;P < .001),pretreatmenttoposttreat-
ment(χ210 = 150.83;P < .001),andpretreatmenttofollow-up(χ210
= 1102.70;P < .001)weresignificant, indicatingsignificantvari-
ability in the amount of improvement between studies, hence
suggesting theexistenceofpossiblemoderators.Wefirstexam-
ined each moderator separately. We then included all the
significant moderators and predictors in a final, composite
multimoderator analysis. Onemoderator was relevant to DCS
participants only (DCS dose) and could not be estimated as a
moderator in thefull samplebecause itwas0forallplacebopar-
ticipants. Hence, we could analyze DCS dose only as a predic-
tor and not as amoderator of outcome in a separate analysis.
Results from the individual moderator analyses are pre-
sented inTable2. Significantmoderators in the individualmod-
erator analyses were then included in the multimoderator
analysis. Only 1 significant moderator emerged: year of pub-
lication. Specifically, themore recent the study, the smaller the
difference between DCS and placebo for pretreatment to fol-
low-up improvement (b = 4.02; 95% CI, 0.59-7.45; P = .02,
d= 0.26). Additional post hoc analyses showed that the over-
all score in theCochraneCollaborationTool forAssessingRisk
of Bias for each individual study (eResults and eTables 5 and
6 in the Supplement) was not a significant moderator of any
of the DCS effects (Table 2).
The analysis of the DCS-relevant predictor, performed
using only the DCS subsample, showed that DCS dosage was
highly skewed (skewness = 3.89). While 428 of 523 partici-
pants (81.8%) received 50 mg of DCS, some received 250 mg
or even 500 mg. To reduce skewness to acceptable levels
(<1.0),54 we used the inverse transformation,54 which re-
duced skewness to−0.31. Theanalysis of the transformedDCS
dosage showed that it was not associated with the outcome
(Table 2).
Risk of Bias Across Studies
Toourknowledge,thismeta-analysisincludes97.6%ofalleligible
data.Theonlymissingstudy50failedtofindanadvantageofDCS
Table 1. Multilevel Model Coefficients for the Effect of D-Cycloserine
vs Placebo in the Augmentation of Exposure-Based Cognitive-Behavior
Therapya (Primary Aims 1 and 2)
Predictor
Regression
Coefficient (SE) P Value
Intercept 50.33 (0.97) <.001b
Group (DCS/placebo)c 0.43 (1.07) .69
Antidepressants 2.39 (1.31) .08
Baseline severity 0.60 (0.04) <.001b
Time pretreatment to
midtreatment
−24.39 (3.95) <.001b
Time pretreatment to
posttreatment
−35.05 (3.85) <.001b
Time pretreatment to follow-up −36.40 (3.11) <.001b
Group × antidepressants 0.80 (2.43) .74
Group × time pretreatment
to midtreatment
−1.66 (1.67) .32
Group × time pretreatment
to posttreatment
−3.62 (1.44) .01b
Group × time pretreatment
to follow-up
−2.98 (1.54) .05
Antidepressants × time
pretreatment to midtreatment
−0.81 (2.19) .71
Antidepressants × time
pretreatment to posttreatment
−2.01 (1.81) .27
Antidepressants × time
pretreatment to follow-up
−4.32 (1.89) .02b
Group × time pretreatment to
midtreatment × antidepressants
−2.23 (3.99) .58
Group × time pretreatment to
posttreatment × antidepressants
−3.67 (3.28) .26
Group × time pretreatment to
follow-up × antidepressants
1.19 (3.51) .73
Abbreviation: DCS, D-cycloserine.
a Antidepressants were included in themodel as an a priori moderator.
b These effects were also significant in the final multimoderator analysis.
c Group was coded as placebo = 0 and DCS = 1.
Figure 2. Group by Time Interaction Effects on the Transformed
Primary OutcomeMeasurea
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Scores are shown at baseline, midtreatment, posttreatment, and follow-up,
according to treatment group. The vertical axis represents the transformed
(ranked) severity score, with higher scores denoting greater symptom severity
(range, 0-100). Error bars indicate 95% CIs.
a Antidepressants were included in themodel as an a priori moderator.
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vs placebo in individualswith posttraumatic stress disorder. In
thatstudy,exposuretherapyplusplaceboperformedsignificantly
betterthanexposuretherapyplusDCS, leadingtoapotentialbias
in favor of DCS owing to the omission of that study.
Additional Analyses
For more detailed information on the effect of DCS by diag-
nosis, we ran our primary analysis separately for each diag-
nosis (eTable 7 in theSupplement). TheadvantageofDCSover
placebowas only significant for thosewith social anxiety dis-
order (eTable 7 in the Supplement). Antidepressants signifi-
cantlymoderatedDCS effects only for participantswithpanic
disorder with or without agoraphobia, which made up the
smallest diagnosis sample in our meta-analysis (n = 77) and
included only 2 studies (eTable 1 in the Supplement).
Sensitivity Analyses
We reran our models excluding the single-session studies by
Gutner et al38 and Rodebaugh et al,41 which were not treat-
ment studies but experimental in nature. In the analysis con-
trolling for antidepressant use as a moderator of the DCS ef-
fects (primary aim 1), participants receivingDCSdidnot show
greater improvement frompretreatment toposttreatment (dif-
ference,−2.85;95%CI,−5.91 to0.21;P = .06;d = −0.21) (eTable
8 in theSupplement).However, effect sizeswere similar to the
original analyses (d = −0.21 vsd = −0.25). Antidepressant use
did not moderate any of the effects of DCS on outcome (pri-
mary aim 2).
Additionally,we repeated the analyses excludingonly the
study by Gutner et al,38 whichwas the only one including pa-
tientswhomaynothavemet the impairment/interference cri-
terion for specific phobia. Results after the exclusion of this
trialwerevirtually identical to thosereportedfor thefull sample
(eTable 8 in the Supplement).
Discussion
Themain findingof this 1-stage IPDmeta-analysiswas thatDCS
showed a statistically significant advantage over placebo at
posttreatment, regardless of the inclusion of treatment with
antidepressants in themodel. This advantage was small (less
than4points ona0-100 scale;d = −0.25). Less consistent evi-
dence was found for the advantage of DCS at follow-up. Fur-
thermore, themultimoderatoranalysis revealed thatonlypub-
lication year was significant, suggesting that more recent
studies tendedtoshowsmallerdifferences in improvementbe-
tweenDCS andplacebo frompretreatment to follow-up (0.26
SDs less improvement for each additional year).
Theaccelerationof treatment effects observed in some in-
dividual trials atmidtreatment21,55 couldnot be confirmedbe-
cause there were no significant midtreatment effects. Our
analyses also failed to confirm the hypothesis that concomi-
tant antidepressantmedicationwouldmoderate the effects of
DCS, as initially suggested by the animal literature28,29 and a
2015 human trial.22
Thenumberof treatment sessionsdidnotmoderate treat-
ment outcomes. It has been suggested that DCS may offer
greater advantage vs placebo when brief treatments are used
because the placebo-treated patients have less chances
to “catch up” with the DCS-treated patients in brief
treatments.27,56 Our analysis did not support this hypothesis
but suggested that the small benefits of DCS at posttreatment
are attenuated during follow-up.
The number of DCS pill administrations was not associ-
ated with the degree of improvement at any time. This find-
ing is not consistent with the concern that DCS efficacy may
decrease with increasing numbers of administrations.24
Neither the timeof administrationnor thedoseofDCShad
aneffect on theoutcomes, although therewas relatively small
variability in the data. Most trials administered the drug ap-
proximately 1hourbefore theexposure session, andmostpar-
ticipants received 50-mg doses.
Although DCSmay exert its effects by enhancing fear ex-
tinction retention, studies have not limited inclusion to par-
ticipants with extinction consolidation deficits. Therefore,
weak effects across trials are perhaps unsurprising. Similarly,
DCS has been administered in these studies independent of
within-session learningexperiences, anotableweaknessgiven
the possibility that DCSmay enhance fearmemory reconsoli-
dation under certain conditions.57 Extinction learning varies
across sessions and patients, and accordingly, DCS may have
inadvertently interfered with exposure efficacy in some pa-
tients and facilitated its efficacy in others.57,58
Strengths and Limitations
Amajor strength of this studywas that we could obtainmore
than 97% of all eligible raw data, which greatly surpasses the
greater than 90% of eligible participants that has been sug-
gestedas a suitable target to achieve.59Apower calculation re-
vealed that, with our combined sample size, we had greater
than 80% power to detect an effect size as small as a Cohen d
value of 0.20 for the treatment effects and individual-level
moderators.This representsasubstantial improvementonpre-
vious aggregate-data meta-analyses,23-26,60 which were only
powered to detect large effect sizes.
This study also had limitations. We had less power to de-
tect study-levelmoderators/predictorsandfor subgroupanaly-
ses. Similarly, there have only been 4 studies using pediatric
samples, which limits the generalizability of our results to
youngerpopulations.Another limitation is thatdifferent stud-
iesuseddifferentoutcomemeasures, and for this reason, these
hadtobetransformedintorankedscores toensureasinglemet-
ric across studies. Finally,wecouldnot examine in-sessionex-
periences as possible moderators of DCS efficacy. For ex-
ample, fear at the end of an exposure therapy session has
emergedas 1possible important variable57 because it hasbeen
shown tomoderateDCSefficacy in 2 studies58,61 aswell as the
efficacy of 2 other pharmacological enhancement strategies
(yohimbine62 and methylene blue63).
Conclusions
We found evidence supporting the short-term superiority of
DCS vs placebo in the augmentation of exposure-based CBT
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for anxiety-relateddisorders andmixed support for themain-
tenance of these benefits at follow-up.While statistically sig-
nificant, the effect sizeswere small. Concomitant antidepres-
sant medication did not significantly moderate the effects of
DCS. None of the prespecified patient-level (eg, age and sex)
or study-level (eg, primarydiagnosis, numberof exposure ses-
sions,DCSdose, timingof administration, andnumber ofDCS
administrations)moderatorswere clearly associatedwithout-
comes.The limitationsofprevious studies and lessons learned
over the past decade call for a next stage of research examin-
ing the efficacy of DCS and other augmentation strategies for
facilitatingexposure therapy,which specifically examines tar-
geted administration as guided by theory and basic research
findings.27,64,65
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